{"id":"administration-of-azd6738","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By inhibiting ATR kinase, AZD6738 disrupts the cellular response to DNA replication stress and double-strand breaks, leading to cell cycle arrest and apoptosis in cancer cells with compromised DNA repair mechanisms.","oneSentence":"AZD6738 is a selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase, which plays a critical role in the DNA damage response pathway.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T05:50:21.493Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors with defective DNA damage response pathways"}]},"trialDetails":[{"nctId":"NCT04704661","phase":"PHASE1","title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-09","conditions":"Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma","enrollment":51},{"nctId":"NCT03462342","phase":"PHASE2","title":"Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2018-03-09","conditions":"High Grade Serous Carcinoma","enrollment":123},{"nctId":"NCT05514132","phase":"PHASE1","title":"A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-09-23","conditions":"Advanced Solid Tumours","enrollment":14},{"nctId":"NCT04090567","phase":"PHASE2","title":"Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-07-28","conditions":"Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8","enrollment":60},{"nctId":"NCT03801369","phase":"PHASE2","title":"AMTEC IIT: Phase 2 Multiarm Study in TNBC","status":"TERMINATED","sponsor":"Gordon Mills, MD, PhD","startDate":"2018-12-12","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":24},{"nctId":"NCT04417062","phase":"PHASE2","title":"Olaparib With Ceralasertib in Recurrent Osteosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-11-24","conditions":"Osteosarcoma, Osteosarcoma Recurrent","enrollment":63},{"nctId":"NCT02813135","phase":"PHASE1, PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":"Pediatric Cancer","enrollment":472},{"nctId":"NCT04699838","phase":"PHASE2","title":"Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Muhammad Furqan","startDate":"2021-04-20","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT06680050","phase":"PHASE2","title":"Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen","status":"RECRUITING","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2025-08-07","conditions":"Non Small Cell Lung Cancer NSCLC","enrollment":21},{"nctId":"NCT03878095","phase":"PHASE2","title":"Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-01-30","conditions":"Malignant Solid Neoplasm, Refractory Cholangiocarcinoma, Refractory Malignant Solid Neoplasm","enrollment":24},{"nctId":"NCT03334617","phase":"PHASE2","title":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-12-18","conditions":"Non-Small Cell Lung Cancer","enrollment":528},{"nctId":"NCT05582538","phase":"PHASE2","title":"Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel","status":"RECRUITING","sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","startDate":"2022-12-15","conditions":"Triple Negative Breast Cancer Metastatic","enrollment":37},{"nctId":"NCT03740893","phase":"PHASE2","title":"PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2019-10-15","conditions":"Breast Neoplasm, Triple Negative Breast Cancer (TNBC), HRD","enrollment":119},{"nctId":"NCT03682289","phase":"PHASE2","title":"Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Rahul Aggarwal","startDate":"2019-01-17","conditions":"Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm","enrollment":89},{"nctId":"NCT06754761","phase":"PHASE1","title":"Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-01-17","conditions":"Neoplasm","enrollment":8},{"nctId":"NCT02937818","phase":"PHASE2","title":"A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-11-28","conditions":"Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma","enrollment":72},{"nctId":"NCT03527147","phase":"PHASE1","title":"Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2018-06-19","conditions":"NHL, DLBCL, Non-hodgkin's Lymphoma","enrollment":30},{"nctId":"NCT03780608","phase":"PHASE2","title":"This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2019-07-30","conditions":"Gastric Adenocarcinoma, Malignant Melanoma","enrollment":61},{"nctId":"NCT03022409","phase":"PHASE1","title":"A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-09-18","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":21},{"nctId":"NCT04239014","phase":"PHASE2","title":"A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2020-08-07","conditions":"Ovarian Cancer","enrollment":""},{"nctId":"NCT03182634","phase":"PHASE2","title":"The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial","status":"UNKNOWN","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2016-12-15","conditions":"Advanced Breast Cancer","enrollment":1150},{"nctId":"NCT01955668","phase":"PHASE1","title":"AZD6738 First Time in Patient Multiple Ascending Dose Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-11","conditions":"11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL),, Prolymphocytic Leukaemia (PLL), B Cell Lymphomas","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Administration of AZD6738","genericName":"Administration of AZD6738","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD6738 is a selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase, which plays a critical role in the DNA damage response pathway. Used for Solid tumors with defective DNA damage response pathways.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}